Albendazole-lipid nanocapsules: Optimization, characterization and chemoprophylactic efficacy in mice infected with Echinococcus granulosus.

Exp Parasitol 2019 Mar 12;198:79-86. Epub 2019 Feb 12.

Unidad de Investigación y Desarrollo en Tecnología Farmacéutica, UNITEFA-CONICET, Ciudad Universitaria, 5000, HUA-Córdoba, Argentina; Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Ciudad Universitaria, 5000, HUA-Córdoba, Argentina. Electronic address:

Cystic echinococcosis (CE), which is caused during the metacestode larval stage of Echinococcus granulosus, is a life-threatening disease and is very difficult to treat. At present, the FDA-approved antihelmintic drugs are mebendazole (MBZ), albendazole (ABZ) and its principal metabolite ABZ sulfoxide (ABZSO), but as these have a therapeutic efficacy over 50%, underlining the need for new drug delivery systems. The aim of this work was the optimization and characterization of previously developed ABZ lipid nanocapsules (ABZ-LNCs) and evaluate their efficacy in mice infected with E. granulosus. LNCs were prepared by the phase inversion technique and characterized in terms of size, surface charge, drug loading, and in vitro stability followed by an in vivo proof-of-concept using a murine model infected with E. granulosus. Stable particle dispersions with a narrow size distribution and high efficiency of encapsulation (≥90%) were obtained. ABZ-LNCs showed a greater chemoprophylactic efficacy than ABZ suspension administered by the oral route as 4 out of the 10 ABZ-LNCs treated mice did not develop any cysts, whereas the infection progressed in all mice from the ABZ suspension group. Regarding the ultrastructural studies of cysts, mice treated with ABZ-LNCs or ABZ suspension revealed changes in the germinal layer. However, the extent of the damage appeared to be greater after ABZ-LNC administration compared to the suspension treatment. These results suggest that ABZ-LNCs could be a promising novel candidate for ABZ delivery to treat CE.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exppara.2019.02.002DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
March 2019
19 Reads

Publication Analysis

Top Keywords

abz suspension
12
infected granulosus
8
mice infected
8
efficacy mice
8
optimization characterization
8
echinococcus granulosus
8
chemoprophylactic efficacy
8
abz
7
abz-lncs
5
mice
5
changes germinal
4
abz-lncs greater
4
nanocapsules abz-lncs
4
prepared phase
4
suspension revealed
4
abz-lncs evaluate
4
evaluate efficacy
4
granulosus lncs
4
greater chemoprophylactic
4
revealed changes
4

Similar Publications